Reference Intervals for ROTEM-tPA: Whole-Blood Fibrinolysis Assessment in Healthy Adults Authors: Anne L. Malte, Kathrine A. Friis, Magnea Heimisdóttir, Julie Mellgaard, Johanne A. Hojbjerg, Erik L. Grove, Julie B. Larsen Published: 2026 ABSTRACT Background Fibrinolysis is essential for maintaining hemostatic balance, and disturbances contribute to bleeding and thrombotic disorders. Rotational thromboelastometry modified with tissue plasminogen activator (ROTEM-tPA) enables dynamic assessment of fibrinolytic capacity and may support diagnostic and prognostic evaluation in clinical settings. The assay has been widely used in clinical research, but the lack of reference intervals in healthy individuals limits standardized interpretation and clinical implementation. Methods We included 122 healthy plasma donors aged 20–69 years with equal sex distribution. Citrated whole blood samples were analyzed using a standardized ROTEM-tPA protocol with exogenous tissue plasminogen activator (tPA) activation (125 ng/mL). Reference intervals were calculated using a non-parametric approach with 90% confidence intervals in accordance with the Clinical and Laboratory Standards Institute (CLSI) EP28-A3c guidelines. Analytical repeatability (coefficients of variation) and associations with age and sex were also evaluated. Results ROTEM-tPA parameters demonstrated consistent performance across age groups and sex. Analytical repeatability was high, reflected by low coefficients of variation. Reference intervals were established for all ROTEM-tPA parameters. For key parameters, reference intervals were clotting time: 45–68 s, amplitude at 10 min: 33–56 mm, maximum clot firmness: 34–61 mm, lysis index at 30 min: 0–97%, lysis index at 45 min: 0–50%, maximum lysis: 92–100%, area under the curve: 3429–6025 mm·100, lysis time: 1412–3211 s, lysis onset time: 720–2182 s, fibrinolysis speed: 2 to 6 mm/min, and time to area under the curve initiation: 404–1314 s. Conclusion We established the first comprehensive reference intervals for ROTEM-tPA in a healthy adult population. These data provide a foundation for standardized interpretation of fibrinolytic dynamics and support clinical application of ROTEM-tPA in bleeding and thrombotic disorders. Introduction Fibrinolysis is a tightly regulated process responsible for the degradation of fibrin clots and restoration of vascular patency, thereby counterbalancing coagulation in health and disease. 1 Clinically, precise regulation of fibrinolysis is essential, as both insufficient and excessive fibrin breakdown can lead to serious complications. The extent of fibrinolysis reflects the balance between plasmin generation, primarily mediated by tissue plasminogen activator (tPA), and inhibitory mechanisms, including plasminogen activator inhibitor 1 (PAI-1), α2-antiplasmin, and thrombin-activatable fibrinolysis inhibitor (TAFI). 2 An imbalance between pro- and antifibrinolytic factors may result in hyper- or hypofibrinolysis, increasing the risk of bleeding or thrombosis. 3 Hyperfibrinolysis can lead to life-threatening blood loss within hours in conditions such as trauma, major surgery, or in association with postpartum hemorrhage. 4 5 This highlights the need for reliable measurements to assess the fibrinolytic capacity and guide timely transfusion and antifibrinolytic therapy. Conversely, hypofibrinolysis has been associated with the development of both arterial and venous thrombosis and is increasingly reported in conditions such as sepsis, coronavirus disease 2019 (COVID-19), cardiovascular disease, and venous thromboembolism (VTE), 6 7 8 where it may contribute to adverse clinical outcomes. Accurate measurement of fibrinolytic capacity is essential to guide clinical decisions. Fibrinolysis has been extensively studied in plasma-based assays, such as turbidimetric clot lysis tests or chromogenic activity assays, which assess the influence of plasminogen activators and plasma inhibitors on fibrin degradation. 9 While these methods provide mechanistic insights, they are limited by a lack of standardization and do not account for the contributions of blood cells, platelets, or endothelium. Viscoelastic assays such as rotational thromboelastometry (ROTEM) or thromboelastography (TEG) enable dynamic, whole blood assessment of clot formation and breakdown, thereby capturing cellular contributions to fibrinolysis. 10 However, standard ROTEM and TEG are insensitive to endogenous hypofibrinolysis, prompting the development of modified protocols that add exogenous fibrinolytic activators, such as tPA or urokinase-type plasminogen activator (uPA). 10 11 12 Multiple protocols have been proposed, but differences in activators, concentrations, and assay conditions limit comparability across studies. 12 To overcome this, we established a standardized ROTEM-tPA protocol using EXTEM reagent as a tissue factor source and a defined tPA concentration, enabling controlled ex vivo induction and quantification of hypofibrinolysis. This protocol has been successfully applied in clinical studies, 13 14 linking impaired fibrinolysis to thrombotic and bleeding complications and adverse outcomes in critically ill patients. Accurate interpretation of fibrinolysis assays requires protocol-specific reference intervals to distinguish normal variation from clinically relevant alterations in fibrinolysis. As assay results are highly dependent on methodological factors, including tPA concentration and analytical conditions, reference intervals should be established in healthy individuals using standardized procedures. 15 Accordingly, and in line with the Clinical and Laboratory Standards Institute (CLSI) recommendations, we aimed to define reference intervals for ROTEM-tPA parameters in healthy adults using our standardized protocol, 16 thereby providing a framework for consistent interpretation in future clinical studies. Methods Sample Collection and Study Population Healthy individuals were recruited among voluntary plasma donors aged 21 to 69 years at the Blood Bank of Aarhus University Hospital between March 2025 and December 2025. A total of 122 healthy individuals were included. In Denmark, blood and plasma donors are unpaid volunteers who must meet nationally defined eligibility criteria and strict health requirements at enrolment and prior to each donation ( Supplementary Table 1 [available in the online version only]). This preselection provided a basis for establishing a healthy reference population. Subjects were randomly selected to cover an even distribution of age and sex in 5-year age groups from 20 to 70 years. We aimed to enroll a minimum of 120 plasma donors as recommended for non-parametric reference interval estimation according to the CLSI EP28-A3c guidelines. 15 All participants received written and oral information about the study and provided written informed consent before inclusion. The study was conducted in accordance with the Declaration of Helsinki and was approved by the Regional Committee on Health Research Ethics (approval number 1-10-72-39-24). Blood samples were collected immediately prior to plasma donation by trained personnel at the Blood Bank. To ensure the inclusion of only healthy reference individuals, eligibility was further assessed using a health questionnaire and interview. Individuals were excluded if they reported current use of hormonal contraceptives or other hormonal medication; intake of non-steroidal anti-inflammatory drugs (e.g., ibuprofen), acetylsalicylic acid-containing medications, or fish oil supplements within the preceding 7 days; a history of venous thrombosis, diabetes, or inherited thrombophilia (factor V Leiden or prothrombin G20210A mutation). Sample Handling Venous blood was obtained by antecubital smooth venipuncture with minimal stasis and collected into 1.8 mL vacuum tubes containing 3.2% sodium citrate (0.109 mol/L; BD Vacutainer, Becton Dickinson). The citrate-to-blood ratio was 1:9. Tubes were gently inverted immediately after collection to ensure adequate mixing and were transported by hand to the laboratory. Whole blood was used for analysis, and samples were allowed to rest for 30 min, including 10 min at 37°C prior to analysis. All analyses were initiated within 60 min of blood collection. Preanalytical conditions were standardized for all participants. Rotational Thromboelastometry Modified with Tissue Plasminogen Activator Rotational thromboelastometry was performed using a ROTEM delta device (Werfen, Munich, Germany). A modified EXTEM assay incorporating tPA was applied as previously described. 16 Undiluted EXTEM reagent served as tissue factor source, and star-tem reagent was used as calcium source in accordance with the standard EXTEM protocol. Bovine serum albumin (1% w/v) was added to the star-tem to stabilize tPA. Human recombinant tPA (Calbiochem, Sigma–Aldrich, Merck, Darmstadt, Germany) was added to the star-tem reagent immediately before analysis to achieve a final concentration of 125 ng/mL tPA in the reaction cup. Analyses were performed at 37°C with a runtime of 60 min. All samples were analyzed in duplicate within a single analytical run, and analytical repeatability was assessed by calculating the coefficient of variation (CV) between duplicate measurements for each ROTEM parameter. Rotational Thromboelastometry Parameters For each sample, the following ROTEM parameters were recorded and analyzed. Clot initiation : coagulation/clotting time (CT, s), clot formation time (CFT, s), α angle (α, degrees), and clot formation rate (degrees). Clot initiation : coagulation/clotting time (CT, s), clot formation time (CFT, s), α angle (α, degrees), and clot formation rate (degrees). Clot propagation and strength : amplitudes at 5, 10, 15, 20, 25, and 30 min (A5, A10, A15, A20, A25, A30, mm), actual clot firmness (mm), maximum clot firmness (MCF, mm), time to MCF (s), maximum velocity (MaxV, mm/min) and time to maximum velocity (MaxV-t, s), shear elastic modulus strength (G), maximum clot elasticity, thrombodynamic potential index, area remaining at 5, 10, 15, 20, 25, and 30 min after lysis onset time (LOT; AR5–AR30, mm/min), and area under the amplitude curve (AUC, mm/min). Clot propagation and strength : amplitudes at 5, 10, 15, 20, 25, and 30 min (A5, A10, A15, A20, A25, A30, mm), actual clot firmness (mm), maximum clot firmness (MCF, mm), time to MCF (s), maximum velocity (MaxV, mm/min) and time to maximum velocity (MaxV-t, s), shear elastic modulus strength (G), maximum clot elasticity, thrombodynamic potential index, area remaining at 5, 10, 15, 20, 25, and 30 min after lysis onset time (LOT; AR5–AR30, mm/min), and area under the amplitude curve (AUC, mm/min). Fibrinolysis : LOT (min), lysis indices at 30 and 45 min (LI30, LI45, %), maximum lysis (ML, %), lysis time (LT, min), fibrinolysis speed (FS, mm/min), and time to attain maximal clot amplitude (t-AUCi, s). Fibrinolysis : LOT (min), lysis indices at 30 and 45 min (LI30, LI45, %), maximum lysis (ML, %), lysis time (LT, min), fibrinolysis speed (FS, mm/min), and time to attain maximal clot amplitude (t-AUCi, s). A detailed description of all ROTEM-tPA parameters is provided in Supplementary Table 2 (available in the online version only). Fibrinolysis speed was calculated as the rate of clot amplitude decline between LOT and LT. 10 14 In cases where LT was recorded, FS was defined as: For samples where LT was not observed, FS was estimated using the ML value and a standardized endpoint at 60 min, according to the formula: The parameter t-AUCi, estimating time to attain maximal clot amplitude after reaching maximal clot formation velocity, was calculated according to Scarlatescu et al. 17 using the formula: Statistical Analysis Reference intervals for ROTEM-tPA parameters were calculated using a non-parametric approach according to the CLSI EP28-A3c guidelines. 15 For each participant, duplicate measurements were averaged to obtain a single value per parameter. Analytical repeatability was assessed as the CV between duplicate measurements using the formula, CV=SDmean×100 . Distributions of each parameter were visually inspected using histograms, Q–Q plots, and boxplots. Associations with age were assessed using Spearman correlation coefficients with Locally Estimated Scatterplot Smoothing (LOESS) for visualization. Potential partitioning by sex and age was evaluated following the recommendations of Lahti et al. 18 For sex-based partitioning, the 2.5th and 97.5th percentiles of combined groups were compared between males and females. For age-based partitioning, predefined age groups were considered if meaningful associations between age and ROTEM-tPA parameters were observed. Non-parametric 2.5th and 97.5th percentiles were used to define the lower and upper reference intervals limits. Bootstrap resampling (5000 iterations) was applied to estimate 90% confidence intervals (CIs) for each limit. All RI and CI values were rounded to two decimal places. Statistical analyses were performed using R (version 4.5.1, R Foundation for Statistical Computing, Vienna, Austria). Results A total of 122 healthy individuals (62 males and 60 females) were included in the study to account for potential dropouts and ensure that the planned sample size was maintained for analysis. Participants were evenly distributed across 5-year age groups ranging from 20 to 70 years. For most parameters, CVs were generally low, ranging from 0.95% (ML) to 25.95% (A30). Higher variability was observed for a few parameters, notably A30 (25.95%), LI30 (25.07%), and LI45 (70.60%; Supplementary Table 3 [available in the online version only]). The distributions of the ROTEM-tPA parameters CT, A10, MCF, LI30, LI45, ML, AUC, LT, LOT, FS, and t-AUCi are shown in Fig. 1 . These parameters were selected because they are the most extensively studied and commonly used in clinical research and practice. The remaining parameters are shown in Supplementary Fig. S1 (available in the online version only). The potential need for partitioning by age and sex was explored visually using scatterplots illustrating associations with age ( Fig. 2 and Supplementary Fig. S2 [available in the online version only]) and boxplots stratified by sex ( Fig. 3 and Supplementary Fig. S3 [available in the online version only]). In addition, partitioning was formally evaluated using Lahti et al.’s rule. 18 Distribution of ROTEM-tPA parameters. Histograms showing the distribution of the ROTEM-tPA parameters; amplitude at 10 min (A10), area under the curve (AUC), clotting time (CT), fibrinolysis speed (FS), lysis index at 30 and 45 min (LI30, LI45), lysis onset time (LOT), lysis time (LT), maximum clot firmness (MCF), maximum lysis (ML), and time-integrated area under the curve (t-AUCi) are shown. Values are shown on the x -axis and frequency on the y -axis. ROTEM-tPA, rotational thromboelastometry modified with tissue plasminogen activator. Association of ROTEM-tPA parameters with age. Age-related distribution of ROTEM-tPA parameters. Scatter plots show individual values of amplitude at 10 min (A10), area under the curve (AUC), clotting time (CT), fibrinolysis speed (FS), lysis index at 30 and 45 min (LI30, LI45), lysis onset time (LOT), lysis time (LT), maximum clot firmness (MCF), maximum lysis (ML), and time-integrated area under the curve (t-AUCi) as a function of age ( x -axis), with parameter levels on the y -axis. The blue line indicates the locally estimated scatter plot smoothing line, illustrating trends across age. ROTEM-tPA, rotational thromboelastometry modified with tissue plasminogen activator. ROTEM-tPA parameters by sex. Boxplots showing the distribution of ROTEM-tPA parameters stratified by sex: amplitude at 10 min (A10), area under the curve (AUC), clotting time (CT), fibrinolysis speed (FS), lysis index at 30 and 45 min (LI30, LI45), lysis onset time (LOT), lysis time (LT), maximum clot firmness (MCF), maximum lysis (ML), and time-integrated area under the curve (t-AUCi). Boxes represent the interquartile range (IQR) with the median indicated by the central line, and whiskers denote variability beyond the IQR. ROTEM-tPA, rotational thromboelastometry modified with tissue plasminogen activator. No meaningful association between ROTEM-tPA parameters and age was observed, and the statistical criteria did not support age-based partitioning. For sex, Lahti et al.’s rule suggested potential statistical justification for partitioning on all parameters. To further explore this, we performed an exploratory, visual assessment by plotting sex-stratified histograms ( Fig. 4 and Supplementary Fig. S4 [available in the online version only]), including the 2.5th and 97.5th percentiles derived from the sex-combined reference intervals. These plots demonstrated substantial overlaps between sexes, with the combined reference interval encompassing observations from both groups across the full distribution. Although modest shifts in central tendency were observed for some parameters, these did not translate into meaningful separation of distributions or clinically relevant changes in reference limits. Based on this overall assessment, sex-based partitioning was not considered justified, and reference intervals were, therefore, established using the combined cohort. Parameter-specific results of Lahti et al.’s partitioning analysis are provided in Supplementary Table 4 (available in the online version only). Sex-stratified reference intervals are provided in Supplementary Table 5 (available in the online version only) for transparency. Distributions of ROTEM-tPA parameters by sex. Histograms showing the distribution of ROTEM-tPA parameters stratified by sex: amplitude at 10 min (A10), area under the curve (AUC), clotting time (CT), fibrinolysis speed (FS), lysis index at 30 and 45 min (LI30, LI45), lysis onset time (LOT), lysis time (LT), maximum clot firmness (MCF), maximum lysis (ML), and time-integrated area under the curve (t-AUCi). Values are shown on the x -axis and frequency on the y -axis for each sex. The red dashed lines indicate the 2.5th and 97.5th percentiles for the combined reference interval. ROTEM-tPA, rotational thromboelastometry modified with tissue plasminogen activator. Table 1 presents the non-parametric reference intervals with 90% confidence limits for CT, A10, MCF, LI30, LI45, ML, AUC, LT, LOT, FS, and t-AUCi parameters. Supplementary Table 6 (available in the online version only) displays the remaining parameters. All parameters are illustrated graphically in Fig. 5 . Table 1Rotational thromboelastometry modified with tissue plasminogen activator reference intervals.Parameter n 2.5th percentile [90% CI]97.5th percentile [90% CI]CT12245 [44–48]68 [66–71]A1012233 [27–37]56 [55–58]MCF12234 [30–39]61 [59–62]LI301220 [0–1]97 [95–99]LI451220 [0–0]50 [35–60]ML12292 [86–96]100 [100–100]AUC1223,429 [2,973–3,845]6,025 [5,868–6,199]LT1211,412 [1,158–1,461]3,211 [3,111–3,449]LOT122720 [635–861]2,182 [2,079–2,316]FS1222 [1–2]6 [5–6]t-AUCi122404 [278–487]1,314 [1,203–1,416]Abbreviations: A10, amplitude at 10 min; AUC, area under the first derivative curve; CI, confidence interval; CT, coagulation time; FS, fibrinolysis speed; LI30/45, lysis index at 30/45 min; LOT, lysis onset time; LT, lysis time; MCF, maximum clot firmness; ML, maximum lysis; t-AUCi, time from maximal clot formation velocity to zero velocity. Rotational thromboelastometry modified with tissue plasminogen activator reference intervals. Abbreviations: A10, amplitude at 10 min; AUC, area under the first derivative curve; CI, confidence interval; CT, coagulation time; FS, fibrinolysis speed; LI30/45, lysis index at 30/45 min; LOT, lysis onset time; LT, lysis time; MCF, maximum clot firmness; ML, maximum lysis; t-AUCi, time from maximal clot formation velocity to zero velocity. Visual representation of ROTEM-tPA parameters derived from clot formation and fibrinolysis curves. The solid line illustrates the median curve, while dashed lines indicate the lower and upper reference limits. The curves are based on key parameters: amplitude at 5 and 10 min (A5, A10), coagulation time (CT), lysis onset time (LOT), lysis time (LT), and maximum clot firmness (MCF). The y -axis represents clot amplitude (mm) and the x -axis represents time (s). Additional lines highlight α-angle (blue) and fibrinolysis speed (red). ROTEM-tPA, rotational thromboelastometry modified with tissue plasminogen activator. Discussion We established reference intervals for the fibrinolysis assay ROTEM-tPA in 122 healthy blood donors using the protocol previously developed by our group. 16 ROTEM-tPA is a whole blood viscoelastic assay based on well-established ROTEM principles designed to assess fibrinolysis in citrated blood. The tPA-modified protocol provides a set of parameters enabling integrated assessment of both clot formation and fibrinolytic dynamics to evaluate the balance between fibrin formation and lysis. Although the method has been applied with varying activators and tPA concentrations, 12 a standardized protocol has recently been proposed to improve reproducibility. 16 Using this approach, we generated reference intervals in accordance with the CLSI guidelines, representing, to our knowledge, the largest dataset of ROTEM-tPA reference intervals in healthy adults. We previously reported normal ranges (2.5th–97.5th percentiles) in 38 healthy blood donors for CT, CFT, α angle, A10, MCF, AUC, LOT, LT, LI30, LI45, and ML. 16 In comparison, our present reference intervals showed a high degree of concordance across most parameters. The modest narrowing of the intervals observed in our present, larger study is consistent with the increased sample size and the expected reduction in variability. Notably, AUC values were slightly higher in our cohort compared with the original protocol. Overall, these findings support the reproducibility and broader applicability of the ROTEM-tPA protocol. The high degree of concordance between the present study and our previously published data, despite the substantially larger sample size, suggests that the reference intervals are robust and may provide a useful framework for laboratories implementing the assay. Nevertheless, as recommended by the CLSI guidelines, local verification should be considered before clinical implementation to confirm the suitability of the intervals under local analytical and population conditions. Such verification can typically be performed in a smaller cohort of healthy individuals and may facilitate adoption of the assay. We observed no age-related differences across the assessed parameters. For some parameters, sex-specific intervals differed slightly, but since differences were moderate and reference intervals overlapped, sex-specific partitioning was not considered justified. These findings are consistent with a previous ROTEM-tPA study by Kuiper et al., 10 who observed a sex-related difference in clotting time (CT) but not in other ROTEM-tPA parameters, thus aligning with reports indicating limited age- and sex-related variation in standard ROTEM parameters. 19 ROTEM-tPA was developed to provide a more detailed and clinically relevant assessment of fibrinolytic capacity in whole blood. Plasma-based assays, such as the clot lysis assay, 9 or measurements of individual fibrinolytic components (e.g., plasminogen, PAI-1, TAFI, α2-antiplasmin), 20 only evaluate the individual components present in plasma and do not reflect the overall fibrinolytic capacity. 21 Thus, assessing whole blood fibrinolytic capacity, incorporating both plasma and cellular components, may provide a more clinically relevant estimate of fibrinolysis. Other whole blood assays to assess fibrinolysis have been developed. Panigada et al. applied exogenous urokinase in a modified TEG assay (urokinase-TEG) and detected its ability to detect hypofibrinolysis in critically ill patients. 11 Similarly, the ClotPro system included assays designed to assess fibrinolytic capacity using exogenous activators under standardized conditions. 22 The Global Thrombosis Test (GTT) also assesses fibrinolysis in whole blood; however, it operates under high shear conditions with platelet activation, whereas ROTEM-tPA assesses fibrinolysis after tissue factor-initiated coagulation using the EXTEM reagent. 23 Because of these mechanistic differences, it has been argued that the GTT may be particularly suited for studying arterial thrombosis. 24 Further studies are needed to clarify the comparative utility, clinical relevance, and appropriate reference intervals of these approaches. The optimal ROTEM-tPA parameters for assessing fibrinolysis remain undefined. In our cohort, commonly used parameters such as CT, MCF, ML, AUC, LT, and LOT showed low intraindividual variability, supporting their reliability for clinical assessment ( Supplementary Table 3 [available in the online version only]). Although LI30 and LI45 exhibited higher variability, likely due to their low absolute values, the overall reference intervals provide a robust foundation for future clinical application. The broader reference intervals observed for LT, LI30, and LI45 likely reflect both biological and methodological factors. Inter- and intraindividual variation in fibrinolytic capacity is expected, even among healthy individuals, owing to differences in the balance of endogenous fibrinolytic regulators, including plasminogen activator inhibitor-1, α2-antiplasmin, and TAFI. 25 26 Furthermore, LI30 and LI45 are determined at fixed time points and are, therefore, particularly sensitive to differences in the onset and kinetics of clot lysis. Consequently, even minor differences in fibrinolytic response may cause substantial variation in these parameters despite near-complete lysis being achieved in almost all participants. Disturbances in fibrinolysis can contribute to both thrombotic and bleeding complications, thus highlighting the clinical importance of assessing fibrinolytic capacity. Establishing reference intervals in a healthy population provides a benchmark to interpret ROTEM-tPA results and may support broader application across diverse patient groups. Although the analysis is not yet part of routine clinical practice, studies in intensive care populations highlight its applicability. In sepsis patients, Brewer et al. found that impaired fibrinolysis measured by ROTEM-tPA was pronounced and that prolonged LTs were associated with 30-day mortality and VTE. 14 Compared with our reference intervals, median values in this cohort showed elevated CT, LOT, LI45, and LT, and reduced ML and FS, with values falling outside the healthy range. Similarly, Mikkelsen et al. demonstrated that worsening acute kidney injury (AKI) was linked to progressively impaired fibrinolysis, yet these patients paradoxically experienced more bleeding events during the first intensive care unit (ICU) week. 13 In AKI stage 3, median CT, LOT, LI45, and LT were elevated, while ML and FS were reduced compared with our reference intervals, underscoring substantial alterations in fibrinolytic activity in critically ill patients. ROTEM-tPA has also demonstrated potential utility in the diagnosis and management of bleeding disorders. In patients with bleeding disorders of unknown cause, the assay revealed hyperfibrinolysis, with CT, LOT, and LT values at the upper range or outside our reference intervals, correlating with low PAI-1 levels. 27 Furthermore, emerging evidence suggests that targeted interventions, such as plasminogen supplementation, can restore fibrinolytic capacity in conditions like disseminated intravascular coagulation, with potential reductions in mortality. 28 In this context, the reference intervals established in our study enable ROTEM-tPA to serve as a key diagnostic tool for identifying patients with hyper- or hypofibrinolysis who may benefit from such therapies. Collectively, these findings emphasize the clinical relevance of standardized, quantitative assessment of fibrinolytic capacity across both thrombotic and bleeding conditions. ROTEM-tPA also has limitations. Some parameters exhibit high intraindividual variability, which may reduce sensitivity to subtle fibrinolytic abnormalities. Results are influenced by technical factors, including reagent quality and sample handling, potentially hampering reproducibility. The use of exogenous tPA added to the EXTEM reagent may introduce preanalytical variability related to pipetting, timing, and sample handling. In contrast, systems such as ClotPro use pre-prepared cartridges with standardized tPA concentrations, which reduce manual handling and potential variability. The development of pre-prepared tPA-containing reagents could be a focus point for other manufacturers in the future. Nevertheless, the ROTEM-tPA protocol used in this study was designed to minimize variability through fixed reagent concentrations and a standardized methodological framework, supporting reproducibility across centers. Lastly, while assessing whole blood fibrinolysis, the assay does not fully replicate in vivo conditions such as vascular shear or endothelial interactions. Furthermore, additional studies are needed to establish the prognostic and therapeutic utility of ROTEM-tPA. Future studies should focus on prospective evaluation of ROTEM-tPA in patient populations at risk of thrombosis or bleeding, such as individuals with VTE, cancer-associated hypercoagulability, or perioperative hypercoagulable states. Such studies could help define which parameters most accurately reflect clinically relevant fibrinolytic activity and validate the prognostic and therapeutic utility of ROTEM-tPA across diverse clinical settings. The establishment of reference intervals in a healthy population is a prerequisite for these efforts.